Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GILTERITINIB Cause Myocardial infarction? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Myocardial infarction have been filed in association with GILTERITINIB (Xospata). This represents 0.2% of all adverse event reports for GILTERITINIB.

6
Reports of Myocardial infarction with GILTERITINIB
0.2%
of all GILTERITINIB reports
2
Deaths
4
Hospitalizations

How Dangerous Is Myocardial infarction From GILTERITINIB?

Of the 6 reports, 2 (33.3%) resulted in death, 4 (66.7%) required hospitalization, and 1 (16.7%) were considered life-threatening.

Is Myocardial infarction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GILTERITINIB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does GILTERITINIB Cause?

Acute myeloid leukaemia (366) Febrile neutropenia (346) Off label use (334) Platelet count decreased (327) Pneumonia (302) Myelosuppression (300) Pyrexia (281) Death (206) Product use issue (189) Hepatic function abnormal (181)

What Other Drugs Cause Myocardial infarction?

ROSIGLITAZONE (17,018) TESTOSTERONE (3,396) ADALIMUMAB (3,214) SACUBITRIL\VALSARTAN (3,120) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (2,391) APIXABAN (2,010) TICAGRELOR (1,749) LENALIDOMIDE (1,712) ETANERCEPT (1,693) METFORMIN\ROSIGLITAZONE (1,640)

Which GILTERITINIB Alternatives Have Lower Myocardial infarction Risk?

GILTERITINIB vs GIMERACIL\OTERACIL\TEGAFUR GILTERITINIB vs GINKGO GILTERITINIB vs GIVINOSTAT GILTERITINIB vs GIVOSIRAN GILTERITINIB vs GLASDEGIB

Related Pages

GILTERITINIB Full Profile All Myocardial infarction Reports All Drugs Causing Myocardial infarction GILTERITINIB Demographics